Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Pfizer Limited (PFIZER.NS)
INR4,704.50
+39.90 (+0.86%)
IN NSE Healthcare Drug Manufacturers - General
Address
The Capital 400051
Mumbai, IN
Mumbai, IN
CEO
Meenakshi Nevatia
Website
pfizerltd.co.in
IPO
2002-07-01
ISIN INE182A01018
Also trades on
Bombay Stock Exchange · PFIZER.BO (INR)
National Stock Exchange of India · PFIZER.NS (INR)
Description
Pfizer Limited operates as a pharmaceutical company, engaged in the development, promotion, sale, and international export of medicinal products. Its diverse product range addresses numerous therapeutic needs, such as those related to the neuro/central nervous system, hormonal balance, cardiovascular health, hemophilia, infectious diseases, gynecology, pain relief, orthopedic conditions, oncology, urology, parasitic infections, gastrointestinal disorders, vaccinations, respiratory ailments, and nutritional supplements. The company markets its offerings predominantly under various brand names through an extensive network of independent distributors. Established in 1950, its corporate headquarters are situated in Mumbai, India.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
INR4,704.50
+39.90 (+0.86%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
25.6K
Beta
0.11
Float Shares
15.12M
Free Float %
33.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.07% | -1.34% | -2.93% | -7.72% | -5.77% | -5.25% | +11.21% | +25.28% | -11.60% | +168.65% | +2,323.54% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
4,704.50
DCF (Unlevered)
6,497.43
+38.1%
DCF (Levered)
8,024.34
+70.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
19.02
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - General: +6.6%+10.5% ★ Q1'26: +6.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%-5.9% Q1'26: -39.6% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+26.1% ★ Q1'26: +93.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+33.6% ★ Q1'26: +35.1% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+53.9% ★ Q1'26: +56.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%+0.0% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.08× ★ Q1'26: 0.07× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2012 actual |
Mar 2013 actual |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 3 Rev. Ana. 2 EPS Ana. |
Mar 2027 2 Rev. Ana. 2 EPS Ana. |
Mar 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
10.92B
est: 10.84B (+0.8%)
|
9.48B
est: 10.47B (-9.4%)
|
18.53B
est: 11.03B (+68.0%)
|
18.53B
est: 18.26B (+1.5%)
|
20.12B
est: 20.30B (-0.9%)
|
19.66B
est: 21.22B (-7.4%)
|
19.69B
est: 20.37B (-3.3%)
|
20.82B
est: 21.96B (-5.2%)
|
21.52B
est: 22.43B (-4.1%)
|
22.40B
est: 22.48B (-0.3%)
|
26.11B
est: 26.60B (-1.9%)
|
24.25B
est: 24.86B (-2.5%)
|
21.93B
est: 22.25B (-1.4%)
|
22.81B
est: 22.36B (+2.0%)
|
25.29B
24.93B – 25.50B
+13.1% YoY
|
27.63B
27.47B – 27.78B
+9.2% YoY
|
29.96B
29.63B – 30.30B
+8.5% YoY
|
| EBITDA |
2.88B
est: 3.25B (-11.5%)
|
7.02B
est: 3.17B (+121.7%)
|
4.00B
est: 8.33B (-52.0%)
|
4.00B
est: 7.26B (-44.9%)
|
4.43B
est: 4.24B (+4.5%)
|
3.56B
est: 5.95B (-40.3%)
|
5.06B
est: 6.45B (-21.5%)
|
5.72B
est: 7.79B (-26.6%)
|
5.46B
est: 8.69B (-37.2%)
|
6.70B
est: 7.44B (-10.0%)
|
7.88B
est: 8.13B (-3.1%)
|
7.70B
est: 8.56B (-10.0%)
|
5.99B
est: 6.68B (-10.3%)
|
7.05B
est: 6.71B (+5.1%)
|
7.59B
7.48B – 7.65B
+13.1% YoY
|
8.29B
8.24B – 8.34B
+9.2% YoY
|
8.99B
8.89B – 9.09B
+8.5% YoY
|
| EBIT |
2.78B
est: 3.03B (-8.3%)
|
6.94B
est: 1.58B (+337.9%)
|
2.69B
est: 6.33B (-57.5%)
|
2.69B
est: 4.10B (-34.4%)
|
3.85B
est: 2.10B (+83.7%)
|
2.93B
est: 4.05B (-27.8%)
|
4.41B
est: 4.10B (+7.5%)
|
5.03B
est: 4.85B (+3.6%)
|
4.81B
est: 5.15B (-6.6%)
|
6.05B
est: 5.18B (+16.6%)
|
7.22B
est: 5.66B (+27.5%)
|
7.05B
est: 5.96B (+18.2%)
|
5.77B
est: 7.12B (-18.9%)
|
6.81B
est: 7.15B (-4.8%)
|
8.09B
7.98B – 8.16B
+13.1% YoY
|
8.84B
8.79B – 8.89B
+9.2% YoY
|
9.59B
9.48B – 9.69B
+8.5% YoY
|
| Net Income |
1.69B
est: 2.87B (-41.0%)
|
5.03B
est: 1.49B (+237.7%)
|
698.19M
est: 5.30B (-86.8%)
|
698.19M
est: 3.71B (-81.2%)
|
3.05B
est: 776.41M (+292.8%)
|
3.37B
est: 3.11B (+8.3%)
|
3.60B
est: 3.25B (+10.6%)
|
4.29B
est: 3.94B (+8.9%)
|
5.09B
est: 4.37B (+16.5%)
|
4.98B
est: 5.15B (-3.4%)
|
6.13B
est: 5.63B (+8.8%)
|
6.24B
est: 5.93B (+5.2%)
|
5.51B
est: 6.09B (-9.4%)
|
7.68B
est: 6.14B (+25.0%)
|
7.25B
6.73B – 8.02B
+18.1% YoY
|
8.67B
8.37B – 8.77B
+19.5% YoY
|
9.44B
9.16B – 9.73B
+9.0% YoY
|
| SGA |
1.48B
est: 2.00B (-25.8%)
|
2.34B
est: 4.19B (-44.3%)
|
3.59B
est: 4.73B (-24.0%)
|
3.59B
est: 7.47B (-51.9%)
|
4.07B
est: 6.70B (-39.3%)
|
4.09B
est: 6.74B (-39.4%)
|
4.21B
est: 6.71B (-37.2%)
|
4.42B
est: 6.99B (-36.8%)
|
4.53B
est: 6.78B (-33.1%)
|
4.27B
est: 7.01B (-39.1%)
|
4.78B
est: 7.66B (-37.6%)
|
3.93B
est: 8.07B (-51.2%)
|
4.34B
est: 4.10B (+5.8%)
|
4.29B
est: 9.36B (-54.2%)
|
4.66B
4.60B – 4.70B
-50.2% YoY
|
5.09B
5.06B – 5.12B
+9.2% YoY
|
5.52B
5.46B – 5.58B
+8.5% YoY
|
| EPS |
61.87
est: 62.75 (-1.4%)
|
168.63
est: 63.40 (+166.0%)
|
15.26
est: 72.87 (-79.1%)
|
66.66
est: 34.85 (+91.3%)
|
66.66
est: 43.83 (+52.1%)
|
73.61
est: 56.75 (+29.7%)
|
78.70
est: 65.68 (+19.8%)
|
93.78
est: 89.85 (+4.4%)
|
111.28
est: 110.29 (+0.9%)
|
108.77
est: 113.05 (-3.8%)
|
133.89
est: 133.08 (+0.6%)
|
136.38
est: 130.48 (+4.5%)
|
120.51
est: 133.01 (-9.4%)
|
167.79
est: 134.23 (+25.0%)
|
163.25
147.10 – 175.40
+21.6% YoY
|
187.33
182.93 – 191.73
+14.8% YoY
|
206.43
200.20 – 212.67
+10.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
6.00B
OE per share TTM
131.07
Owner's Yield
2.69%
Maintenance CapEx ratio
3.30%
Maint CapEx / Avg PPE
7.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 14 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 460.3K | 0.06% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 32.9K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 14.6K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.63M | 0.06% |
| 5 | Vanguard ESG International Stock ETF VSGX | 0.00% | 29.9K | 0.10% |
| 6 | Vanguard Total International Stock ETF VXUS | 0.00% | 2.04M | 0.05% |
| 7 | Vanguard Total World Stock ETF VT | 0.00% | 199.9K | 0.06% |
| 8 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 2.6K | 0.22% |
| 9 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 7.9K | 0.22% |
| 10 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 4.2K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
4.92M
Shares Outstanding
45.75M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Meenakshi Nevatia | MD, Chief Executive Officer & Director | 95M | female |
| Pazhania Pillai Rengan | Whole-Time Director & Executive Director of Plant Operations | 15M | male |
| Prajeet Nair | Director of Corporate Services, Company Secretary & Compliance Officer | 5M | male |
| Reshma Parida | Senior Director of People Experience | — | female |
| Anil Pattanshetty | Senior Director of Business Operations | — | male |
| Sharad Goswami | Senior Director of Policy & Public Affairs | — | male |
| Chaitanya Nadkarni | India Digital Client Partner Lead & Director of Digital | — | male |
| Deepak Rakheja | Strategic Partnerships, Channel Development & International Neighbouring Markets Lead | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PFIZER.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
